View:
Filed by Health Sciences Acquisitions Corporation 2
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Health Sciences Acquisitions Corporation 2
Commission File No. 001-39421
Date: July 5, 2022
The following social media posts are being filed in connection with the proposed business combination of Health Sciences Acquisitions Corporation 2 and Orchestra BioMed, Inc.
Twitter
Big news today – we announced a strategic collaboration with #Medtronic, closing of a $110 million private equity financing and merger plans to list on #Nasdaq! See our release
https://globenewswire.com/en/news-releas...
Linkedin
Today is a day of major milestones for @OrchestraBioMed! We announced a strategic collaboration with #Medtronic for our Backbeat Cardiac Neuromodulation Therapy, closing of a $110 million private financing with investors
including #Medtronic, #Terumo, #RTWInvestments and #PerceptiveAdvisors, and a business combination agreement with Health Sciences Acquisitions Corporation 2 that would lead to listing our company on #NASDAQ under the ticker “OBIO”. See our press release with all the exciting news. https://lnkd.in/gkgh8QH7
Important Information for Investors and Shareholders
This communication relates to the proposed business combination (the “Business Combination”) of Health Sciences Acquisitions Corporation 2, a Cayman Islands
exempted company (“HSAC2” or the “Company”), and Orchestra BioMed, Inc., a Delaware corporation (“Orchestra”) pursuant to an
Agreement and Plan of Merger Agreement (the “Merger Agreement”). In connection with the proposed Business Combination, HSAC2 intends to file a registration statement on Form S-4 with the SEC, which will include
a document that serves as a prospectus and proxy statement of HSAC2, referred to as a “proxy statement/prospectus.” The proxy statement/prospectus will be sent to all HSAC2 shareholders. HSAC2 also will file other documents regarding the Business
Combination and related transactions with the SEC. Before making any voting decision, investors and security holders of HSAC2 are urged to read the registration statement, the proxy statement/prospectus and all other
relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed Business Combination and related transactions.
Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the
SEC by HSAC2 through the website maintained by the SEC at www.sec.gov or by directing a request to: Health Sciences Acquisitions Corporation 2, 40 10th Avenue, Floor 7,
New York, NY 10014.
Forward Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements within the meaning of “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “shall,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,”
“would,” “plan,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking.
These forward-looking statements may include, but are not limited to, statements regarding estimates and forecasts of the closing of the Business Combination, achievement of the conditions necessary for the closing of the Business Combination,
achievement of the earnout consideration, other performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this communication and on the current expectations of the
respective management teams of HSAC2 and Orchestra and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor
as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the
control of HSAC2 and Orchestra. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal
conditions.
These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the inability of the parties to successfully or timely consummate the Business
Combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect HSAC2 or the expected benefits of the Business Combination, if not obtained;
the failure to realize the anticipated benefits of the Business Combination; matters discovered by the parties as they complete their respective due diligence investigation of the other parties; the ability of HSAC2 prior to the Business Combination,
and the combined company following the Business Combination, to maintain the listing of their respective shares on Nasdaq; costs related to the Business Combination; the failure to satisfy the conditions to the consummation of the Business
Combination, including the approval of the Merger Agreement and the transactions contemplated by the Business Combination by the shareholders of HSAC2, the satisfaction of the minimum cash requirements of the Merger Agreement following any
redemptions by HSAC2’s public shareholders; the risk that the Business Combination may not be completed by the stated deadline and the potential failure to obtain an extension of the stated deadline; the outcome of any legal proceedings that may be
instituted against HSAC2 or Orchestra related to the Business Combination, expiration of, or failure to extend, the period of time HSAC2 is afforded under its organizational documents and the final prospectus of HSAC2, dated August 3, 2020, to
consummate the initial business combination with Orchestra; the attraction and retention of qualified directors, officers, employees and key personnel of HSAC2 and Orchestra prior to the Business Combination and the combined company following the
Business Combination; the ability of the combined company to compete effectively in a highly competitive market; the ability to protect and enhance the combined company’s corporate reputation and brand; the impact from future regulatory, judicial,
and legislative changes in the combined company’s industry; and, the uncertain effects of the COVID-19 pandemic; future financial performance of the combined company following the Business Combination; the ability of Orchestra and the combined
company to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; the ability of the combined company to generate sufficient revenue; the ability of the combined company to protect its intellectual property from
competitors; the combined company’s ability to execute its business plans and strategy; and those factors set forth in documents of HSAC2 filed, or to be filed, with the SEC. The foregoing list of risks is not exhaustive.
If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional
risks that neither HSAC2 nor Orchestra presently know, or that HSAC2 and Orchestra currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking
statements reflect HSAC2’s and Orchestra’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this communication should be regarded as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of
the date they are made and are qualified in their entirety by reference to the cautionary statements herein and the risk factors of HSAC2 and Orchestra described above. HSAC2 and Orchestra anticipate that subsequent events and developments will cause
their assessments to change. However, while HSAC2 and Orchestra may elect to update these forward-looking statements at some point in the future, they each specifically disclaim any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as representing HSAC2’s or Orchestra’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Participants in the Solicitation
HSAC2 and its directors and executive officers may be deemed participants in the solicitation of proxies from HSAC2’s shareholders with respect to the proposed Business Combination. A list of the
names of those directors and executive officers and a description of their interests in HSAC2 is contained in HSAC2’s Annual Report on Form 10-K, which was filed with the SEC on March 31, 2022 and is available free of charge at the SEC’s website at
www.sec.gov, or by directing a request to Health Sciences Acquisitions Corporation 2, 40 10th Avenue, Floor 7, New York, NY 10014. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus
for the proposed Business Combination when available.
Orchestra and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of HSAC2 in connection with the proposed Business
Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when
available.
No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any
securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of
a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.